Pet Partners and Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot Pet Partners and the Baxter Foundation, the charitable arm of Baxter…
Merck & Co., Inc. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML) Merck & Co.—known as MSD outside the United States and Canada—and…
Novo Nordisk A/S Reports Up to 2.16% HbA1c Reduction with Triple Agonist UBT251 After 24 Weeks in Phase 2 Trial Among Chinese Patients with Type 2 Diabetes The United Laboratories…
Kallisio Secures CE Mark for Stentra™ Precision Oral Immobilization System Kallisio has announced a significant regulatory milestone with the CE certification of its innovative Stentra intraoral positioning system under the…
Aerin Medical Achieves Milestone of Treating Over 200,000 Patients with Its Minimally Invasive Therapies for Chronic Nasal Disorders Aerin Medical Inc., a recognized innovator in minimally invasive therapies for chronic…
FDA Clears Corcept’s Lifyorli™ (relacorilant) in Combination with Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer Treatment Corcept Therapeutics Incorporated has announced a major regulatory milestone with the approval of its novel therapy,…
Seaport Therapeutics, Founded by PureTech, Reports Science Translational Medicine Publication Highlighting GlyphAllo™ (SPT-300) as a First-in-Class Triglyceride-Mimetic Prodrug Achieving Therapeutic Drug Levels in Humans PureTech Health plc has highlighted a…
Imperative Care Launches CLEAR-IT Clinical Study to Advance Standards in Peripheral Thromboembolism Treatment Imperative Care Inc has announced a significant milestone in its efforts to advance treatment options for patients…
Incyte Reports New Appointments to Its Executive Leadership Team Incyte has announced a series of key leadership appointments within its executive team, signaling a strategic move to strengthen its organizational…
Poxel Announces Drawdown of Additional Tranche D PDR Bonds Under Continuation Plan POXEL SA, a biopharmaceutical firm specializing in innovative therapies for serious chronic diseases with metabolic origins, including metabolic…
Ono Pharma Files Application in Japan for Ripretinib (DCC-2618) to Treat Advanced Gastrointestinal Stromal Tumors Ono Pharmaceutical, headquartered in Osaka, Japan, under the leadership of President Toichi Takino, has announced…
Element Science Earns Spot on Fast Company’s 2026 List of the World’s Most Innovative Companies Element Science has earned a place on Fast Company’s prestigious list of the World’s Most…